抑制T细胞增殖的抗CD98重链单克隆抗体的建立

目的寻找能调节T细胞功能的相关分子,进行与T细胞介导的自身免疫性疾病相关的研究。方法收集BALB/c小鼠脾细胞,免疫Wistar大鼠,进行细胞融合,建立杂交瘤细胞系。筛选得到43株能调节T细胞功能的杂交瘤细胞系,对其中一株最能抑制T细胞增殖的杂交瘤细胞系进行了进一步的深入研究。结果显示其目标分子是CD98重链,同时后续实验显示抗CD98单克隆抗体能抑制纤连蛋白介导的细胞分布,但不影响氨基酸转运。而且混合淋巴细胞反应显示该抗体能显著抑制T细胞增殖反应。结论抗CD98单克隆抗体能有效抑制T细胞增殖,有望将本抗体用于T细胞介导的自身免疫性疾病的相关预防及治疗中。     

CD4+CD25+调节性T细胞与肿瘤免疫

调节性T细胞是一类具有免疫抑制作用,调节自身T细胞功能的T细胞亚群,与维持免疫耐受、抑制自身免疫性疾病有关,CD4＋CD25＋调节性T细胞是其重要组成部分.该文介绍CD4＋CD25＋调节性T细胞在癌症患者免疫系统中的失调现象、机制和以其为靶点的免疫治疗方式.     

CD4+CD25+调节性T细胞

调节性T细胞(regulatory T cells,Treg)是机体维持自身耐受的重要组成部分。CD4^ CD25^ Treg细胞来源于胸腺,其主要功能是抑制自身反应性T细胞,并且其作用是通过直接的Treg-T效应细胞之间的相互接触方式来实现的。CD4^ CD25^ Treg细胞可分泌多种抑制性细胞因子,但与其抑制功能关系并不明确,目前有证据表明GITR和Foxp3与CD4^ CD25^ Treg细胞的抑制功能有关,并且Foxp3已作为CD4^ CD25^ Treg细胞的特异性标志。通过IL-10、TGF-β等抑制性细胞因子、imDC以及转基因技术可以产生具有免疫抑制功能的调节性T细胞。调节性T细胞在免疫相关性疾病、肿瘤免疫和抗感染免疫等方面具有重要意义。     

影响CD4+CD25+T细胞分化发育的细胞分子机制

免疫耐受的精髓即机体对外界病原体抗原产生免疫应答的同时对自身抗原不应答.近两年对CD4 CD25 调节性T细胞(CD4 CD25 regulatory T cell, Treg)所发挥的免疫耐受功能的研究取得了令人瞩目的长足进展,对此群细胞所具有的维持外周免疫耐受的独特地位已无可争议.但调节性T细胞的多种生物学特征特别是Treg细胞分化发育的分子机制与信号需求并不清楚,因此探索有关Treg的发生发育及其影响机制已成为近两年研究Treg细胞的热点.综述最近的相关研究数据,了解胸腺以及外周影响Treg细胞分化发育和功能产生的多种细胞分子机制,有助于进一步研究此群细胞的功能及其在抑制自身免疫性疾病、诱导移植耐受等方面的应用.     

内皮细胞的免疫学功能

血管内皮细胞（Endothelial cell,EC)通过表达多种免疫相关分子与或影响免疫过程,能以MHC－II类分子限制性方式提呈抗原,同时可通过B7／CD28,CD40／CD40L,CD58／CD2等途径向T细胞提供活化所必需的共刺激信号,EC表达的粘附分子介导EC与不同白细胞亚群间相互作用,对白细胞粘附穿过EC进入组织间隙参与炎症反应,淋巴细胞归巢或再循环等过程有重要意义,EC可表达补体调节因子调节补体系统活化,EC受多种因素激活后所表达的免疫相关分子表达上调,并产生多种细胞因子,参与机体的炎症反应及免疫应答,是重要的免疫调节细胞,本文将对EC免疫学方面的功能作简要综述。     

Sirtl在免疫调节中的研究进展

沉默信息调节因子1(Sirt1),属于Ⅲ类组蛋白去乙酰化酶,是依赖于NAD+的去乙酰化酶,具有高度保守的催化结构域,通过对多种底物进行去乙酰化作用在机体内参与一系列生物学活动.Sirt1去乙酰化调节多种转录因子活性,介导包括细胞凋亡、自噬、代谢、蛋白质内稳态、炎症等多种功能.近年研究发现,Sirt1在免疫调节中也具有重要作用,Sirtl可调节巨噬细胞功能,参与T细胞增殖、分化,在维持T细胞耐受中也具有一定作用,Sirt1还可能通过CD38介导的相关途径调节B细胞功能.大量文献报道多种疾病的发生与Sirt1活性水平有关,Sirt1活性受损可增加炎症和自身免疫性疾病的发生.本文通过综述Sirtl对NF-κB、AP-1信号通路的调节机制,来明确Sirt1在天然免疫和获得性免疫应答中的作用,为临床治疗自身免疫性疾病提供理论依据和可能的治疗靶点.     

肿瘤坏死因子受体相关因子3调节调节性T细胞的效应器功能和体液免疫应答

调节性T细胞（Treg细胞）控制免疫应答的不同方面,但其如何调控效应器功能尚不完全明确。该研究鉴定了肿瘤坏死因子受体相关因子3（TRAF3）是 Treg细胞的功能效应器。在 Treg细胞中特异性敲除TRAF3后,CD4＋ T细胞稳态受损,表现为Th1型效应／记忆T细胞增加。此外,Treg细胞中TRAF3敲除还增加抗原刺激引起的滤泡辅助性T细胞（TFH细胞）激活,伴随着生发中心形成增加及高亲和性IgG抗体产生。虽然TRAF3敲除并没有减少Treg细胞的总比例,但减少滤泡调节性T细胞（TFR细胞）的抗原刺激产生。Treg细胞中TRAF3信号通路是保持较高水平可诱导共刺激分子（ICOS）所必需的,也是TFR细胞生成和抑制抗体反应所必需的。该研究表明,TRAF3作为Treg细胞的功能效应器,具有调节抗体反应的功能,提示其在Treg细胞介导ICOS表达中起重要作用。     

白细胞介素21的生物学功能及其抗肿瘤效应

白细胞介素21（IL-21）属于I类细胞因子,主要由活化的CD4＋T产生,作用于免疫系统中的大部分骨髓、淋巴细胞,具有广泛的生物学功能,是联系主动免疫与被动免疫的中间因子。IL-21能够调节体液和细胞介导的免疫应答,促进T细胞增殖分化,调节B细胞的增殖分化与调亡,增强NK细胞的细胞毒性作用与免疫监督功能。此外,IL-21还具有抗肿瘤作用,与其他细胞因子、疫苗等联合应用,可增强其抑制肿瘤细胞生长的功能。该文综述了IL-21的生物功能及其应用于抗肿瘤治疗的研究前景。     

活化/抑制CD59 对T 淋巴细胞增殖的影响

目的：研究活化/抑制CD59 分子对T 细胞增殖的影响。方法：Jurkat细胞分别电转入pSUPER-siCD59 质粒及用CD59 活化 抗体刺激。激光共聚焦显微镜下观察细胞的电转情况及CD59 分子在细胞膜上的分布及表达;MTT 比色法检测细胞的增殖。 Western blot检测CD59 分子表达及T细胞活化相关蛋白ZAP70磷酸化水平。结果：激光共聚焦显微镜下可见电转染细胞表达绿 色荧光,转染效率约为40%。转染pSUPER-siCD59 质粒后CD59荧光强度强度降低,CD59 分子均匀分布于细胞膜与正常Jurkat 细胞分布一致。抗体活化后CD59 在细胞膜成簇状分布。抗体活后细胞增殖速率和磷酸化ZAP70 的蛋白表达水平均高于正常组 （P<0.05）,而细胞电转质粒后则恰恰相反。结论：CD59 通过与信号转导分子的相互作用促进T 细胞活化增殖。     

草鱼CD8α和CD207的表达及抗细菌免疫的功能研究

为探讨树突状细胞(Dendritic cells, DCs)表面重要的表型分子CD8α和CD207在草鱼(Ctenopharyngodon idella) DCs抗细菌免疫应答中的作用,实验从草鱼DCs的cDNA中扩增CD8α和CD207胞外区,构建重组表达质粒pET-32a-CD8α/CD207,并转化到感受态细胞Transetta (DE3),表达纯化后制备CD8α和CD207多克隆抗体。利用qPCR、Western Blot及流式细胞术揭示草鱼CD8α和CD207在抗细菌免疫过程中发挥的功能。结果显示,制备的草鱼CD8α和CD207多克隆抗体既可以识别原核表达的重组蛋白,也能识别鱼体内和培养细胞的内源性蛋白。从功能上看,灭活嗜水气单胞菌处理草鱼DCs后,在24h内, CD8α和CD207的表达量均有显著上调(P<0.05);且CD8α和CD207分子在草鱼DCs呈递抗原刺激混合淋巴细胞增殖这一过程中发挥重要作用。因此,草鱼DCs表现出与哺乳动物相似的保守免疫表型和功能,研究结果为阐明草鱼DCs介导的适应性免疫调节机制奠定基础。     

Manipulation of CD98 resolves type 1 diabetes in nonobese diabetic mice

The interplay of CD4(+) and CD8(+) T cells targeting autoantigens is responsible for the progression of a number of autoimmune diseases, including type 1 diabetes mellitus (T1D). Understanding the molecular mechanisms that regulate T cell activation is crucial for designing effective therapies for autoimmune diseases. We probed a panel of Abs with T cell-modulating activity and identified a mAb specific for the H chain of CD98 (CD98hc) that was able to suppress T cell proliferation. The anti-CD98hc mAb also inhibited Ag-specific proliferation and the acquisition of effector function by CD4(+) and CD8(+) T cells in vitro and in vivo. Injection of the anti-CD98hc mAb completely prevented the onset of cyclophosphamide-induced diabetes in NOD mice. Treatment of diabetic NOD mice with anti-CD98hc reversed the diabetic state to normal levels, coincident with decreased proliferation of CD4(+) T cells. Furthermore, treatment of diabetic NOD mice with CD98hc small interfering RNA resolved T1D. These data indicate that strategies targeting CD98hc might have clinical application for treating T1D and other T cell-mediated autoimmune diseases.     

Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28

CD28 is expressed abnormally on human multiple myeloma (MM) cells but the significance had not been identified until now. In this paper, we are suggesting that abnormal expression of CD28 might be a marker of tumour progression. We therefore took the approach of generating a hybridoma cell line capable of secreting agonist monoclonal antibody directed against human CD28 (agonist anti-CD28 mAb) and then determined the expression of CD28 molecules on the MM cell lines U266 and XG1. The biological effects of agonist anti-CD28 mAb on cell growth and proliferation of U266 and XG1 cell lines were then analysed. Our results showed that the expression of CD28 on U266 and XG1 was significantly higher than that of PBTC or Jurkat cells. We found that by adding the agonist anti-CD28 mAb to cultures of U266 and XG1 cells their rate of growth and proliferation was obviously inhibited. Further morphological and molecular analyses found that U266 and XG1 incubated with agonist anti-CD28 mAb showed signs of nuclear condensation, chromatin marginal changes, cells membrane breaking, and cytoplasmic shrinkage. Vacuoles and apoptotic bodies were also observed using a transmission electron microscope and the development of typical DNA laddering patterns were found by the use of electrophoresis assays, suggesting that U266 and XG1 cells were undergoing apoptosis induced by agonist anti-CD28 mAb in vitro.     

Anti-CD45 inhibition of human B cell proliferation depends on the nature of activation signals and the state of B cell activation. A study with anti-IgM and anti-CDw40 antibodies

The proliferation of human peripheral and tonsillar B cells stimulated with the anti-CDw40 mAb 626.1 and/or anti-IgM antibody (Ab) in the presence of anti-CD45 mAb A.1.1 was investigated. The anti-CD45 mAb suppressed the anti-CDw40-stimulated proliferation of peripheral blood B cells but had no effect on the proliferation of unfractionated tonsillar B cells stimulated similarly. When tonsillar B cells were separated according to their sizes, the anti-CDw40-induced proliferation of small tonsillar B cells was inhibited by the anti-CD45 mAb, whereas large tonsillar B cells were resistant. In contrast, anti-IgM-induced proliferation of human B cells was always significantly inhibited by the anti-CD45 mAb regardless of cell size and tissue origin. The anti-CD45 mAb also inhibited the anti-IgM-induced initial rise in intracellular [Ca2+] and the G0-G1 cell cycle transition of small tonsillar B cells. However, co-stimulation with anti-IgM/anti-CDw40 Ab resulted in the resistance to the anti-CD45 inhibitory effect on proliferation of peripheral blood B cells and the majority of tonsillar B cells. In contrast, B cell proliferation co-stimulated with anti-IgM Ab/and B cell growth factors were always suppressed by the anti-CD45 mAb. These results demonstrate that certain activational signal mechanisms utilized by anti-CDw40/anti-IgM Ab and anti-IgM Ab/B cell growth factors are different in that B cells stimulated with these agents differ in their sensitivity to the anti-CD45 mAb. Moreover, both the activational state of human B cells and the nature of activation signals given determine their response to the inhibitory signals delivered by the anti-CD45 mAb.     

Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the alpha-chain of the human interleukin-2 receptor.

The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 mAbs recognizing two different epitopes on the human T-lymphocyte antigen, CD4. The chimerized mAbs are produced at levels corresponding to those of the original hybridoma cell lines. With respect to activation of human complement, the individual Abs are negative; however, when used in combination, complement activation was performed. When applied in combination, they were found to modulate the CD4 antigen, whereas the individual mAb do not display this property. Individually they mediate an up to 60% inhibition of the mixed lymphocyte reaction (MLR). However, by combination of an anti-CD4 mAb with one directed against the alpha-chain of the human IL2 receptor, nearly 100% inhibition of the MLR was achieved, even with reduced dosage of the mAbs. Our data suggest that the combination of an anti-CD4 mAb and an anti-IL2R alpha chain mAb is more effective with respect to immunosuppression than each mAb by itself, indicating that this mAb cocktail could be a new strategy for immunosuppressive therapy.     

Stimulation via the CD3 and CD28 molecules induces responsiveness to IL-4 in CD4+CD29+CD45R- memory T lymphocytes

Although both IL-2 and IL-4 can promote the growth of activated T cells, IL-4 appears to selectively promote the growth of those helper/inducer and cytolytic T cells which have been activated via their CD3/TCR complex. The present study examines the participation of CD28 and certain other T cell-surface molecules in inducing T cell responsiveness to IL-4. Purified small high density T cells were cultured in the absence of accessory cells with various soluble anti-human T cell mAb with or without soluble anti-CD3 mAb and their responsiveness to IL-4 was studied. None of the soluble anti-T cell mAb alone was able to induce T cell proliferation in response to IL-4. A combination of soluble anti-CD3 with anti-CD28 mAb but not with mAb directed at the CD2, CD5, CD7, CD11a/CD18, or class I MHC molecules induced T cell proliferation in response to IL-4. Anti-CD2 and anti-CD5 mAb enhanced and anti-CD18 mAb inhibited this anti-CD3 + anti-CD28 mAb-induced T cell response to IL-4. In addition, anti-CD2 in combination with anti-CD3 and anti-CD28 mAb induced modest levels of T cell proliferation even in the absence of exogenous cytokines. IL-1, IL-6, and TNF were each unable to replace either anti-CD3 or anti-CD28 mAb in the induction of T cell responsiveness to IL-4, but both IL-1 and TNF enhanced this response. The anti-CD3 + anti-CD28 mAb-induced response to IL-4 was exhibited only by cells within the CD4+CD29+CD45R- memory T subpopulation, and not by CD8+ or CD4+CD45R+ naive T cells. When individually cross-linked with goat anti-mouse IgG antibody immobilized on plastic surface, only anti-CD3 and anti-CD28 mAb were able to induce T cell proliferation. These results indicate that the CD3 and CD28 molecules play a crucial role in inducing T cell responsiveness to IL-4 and that the CD2, CD5, and CD11a/CD18 molecules influence this process.     

Human resting B lymphocytes can serve as accessory cells for anti-CD2-induced T cell activation.

Although resting B cells are poor accessory cells for signals transmitted through the TCR/CD3 complex, we report that these B cells can support T cell proliferation when T cell activating signals are delivered through CD2. This was first suggested when leucine methyl ester treatment of PBMC abolished proliferation induced by anti-CD3, but not by the accessory cell-dependent anti-CD2 mAb combination, GT2 and OKT11. Then we demonstrated that unstimulated, resting B cells could support the proliferation of both CD4+ and CD8+ T cells. Aggregated IgG inhibited proliferation, suggesting that anti-CD2 mAb bound to T cells were cross-linked by attachment to B cell FcR. Two lines of evidence suggested that lymphocyte function-associated Ag-1/intercellular adhesion molecule-1 interaction was crucial for anti-CD2-induced proliferation. First, proliferation was blocked by mAb against these adhesion molecules. Second, intercellular adhesion molecule-1 expression rapidly increased on resting B cells after the addition of anti-CD2, but not anti-CD3. This was of interest because fixed monocytes, but not fixed B cells, were able to support the proliferative response. In contrast to lymphocyte function-associated Ag-1/intercellular adhesion molecule-1, CD28/B7 interaction was not required for anti-CD2-induced proliferation, although ligation of these molecules provided important costimulatory signals for stimulation by anti-CD3. Finally, neutralizing antibodies against IL-1 alpha, IL-1 beta, and IL-6 showed only modest inhibitory effects on T cell proliferation. The addition of IL-1 and/or IL-6 to T cells failed to substitute for accessory cells and were only partially effective with fixed B cells. Further evidence of a linkage between CD2 and CD45 isoforms was obtained. Anti-CD45RA, but not anti-CD45RO, potentiated anti-CD2-induced T cell proliferation. These studies have revealed a novel role for resting B cells as accessory cells and have documented costimulatory signals that are important for this effect. Because Ag-presentation by resting B cells to T cells generally leads to T cell nonresponsiveness, it is possible that this tolerogenic signal may be converted to an activation signal if there is concurrent perturbation of CD2 on T cells.     

Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules.

The capacity of purified fibronectin to costimulate human T cell DNA synthesis was examined. Low concentrations of immobilized fibronectin, but not soluble fibronectin, augmented anti-CD3-induced proliferation of highly purified human T cells. In the absence of anti-CD3 stimulation, immobilized fibronectin did not induce T cell proliferation alone or in the presence of IL-2 or phorbol dibutyrate. Although fibronectin is present in high concentrations in the serum, immobilized fibronectin was able to costimulate T cell proliferation when cells were cultured in serum-containing medium. Immobilized collagen type I did not enhance anti-CD3 stimulated T cell responses, whereas gelatin (denatured collagen) and laminin were able to enhance anti-CD3 stimulated T cell responses modestly. The effects of gelatin, however, appeared to be indirect, because it could not enhance responses in medium devoid of fibronectin. Immobilized fibronectin enhanced anti-CD3 induced proliferation of both CD45RA dim and CD45RA bright subsets within both the CD4+ and CD8+ subpopulations of T cells, although cells with the CD45RA dim phenotype were costimulated by lower concentrations of immobilized fibronectin. Enhancement of anti-CD3 induced proliferation by immobilized fibronectin was completely inhibited by a mAb to CD29, the integrin beta 1-chain (4B4) and not by a variety of other mAb. In contrast to its effects on proliferation, 4B4 only partially blocked T cell binding to anti-CD3 and fibronectin-coated macrowells. These findings suggested that the interaction between fibronectin and its receptor transduced a signal to the T cell and did not merely stabilize the interaction between anti-CD3 and the CD3 complex. Further experiments confirmed this observation. Thus fibronectin could enhance anti-CD3 responses when it was immobilized to a separate surface. The augmentation of anti-CD3 stimulated proliferation induced by immobilized fibronectin was also inhibited partially by mAb to either VLA-4 or VLA-5 and completely by a combination of the two mAb. The mAb to VLA-4 not only blocked the capacity of immobilized fibronectin to enhance anti-CD3-induced T cell proliferation but also directly costimulated T cell responses. Thus, at least two fibronectin receptors are involved in fibronectin-mediated costimulation of T cell proliferation. These studies indicate that signals are transduced through the fibronectin receptors, VLA-4 and VLA-5, that augment T cell responses and therefore implicate the extracellular matrix protein fibronectin as an important influence regulating T cell responsiveness in vivo.     

Generation and characterization of hamster-mouse hybridomas secreting monoclonal antibodies with specificity for lipopolysaccharide receptor.

Experiments are described for the partial purification of the 80-kDa LPS binding protein expressed on macrophages and lymphocytes. This partially purified Ag was used to immunize adult Armenian hamsters and splenocytes from immunized animals were fused with murine myeloma cell lines. Hybridoma cell culture supernatants containing mAb were screened by ELISA for positive binding to the immunizing Ag, murine splenocytes and the murine 70Z/3 pre B cell and for an absence of binding to sheep E. Positive clones were further screened for reciprocal competitive binding with LPS on spleen cells and ability to modulate B lymphocyte mitogenic activity. Two hybridoma cell lines secreting IgM monoclonals, termed mAb3D7 and mAb5D3, were identified that satisfied all of the selection criteria. These hybridoma cell lines were subcloned and expanded. Binding of one (mAb3D7) was abrogated by treatment of Ag with mild periodate; binding of the second (mAb5D3) was destroyed by digestion of Ag with proteinase K. Binding specificity for mAb5D3 has been confirmed by ELISA using highly purified 80-kDa protein. These mAb have been of value in establishing that the 80-kDa LPS binding protein previously identified may serve as a specific functional receptor for LPS.     

Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.

We developed a culture system for the rapid generation of CD4+ T cells that have both helper and killer functions. CD4+ T cells isolated from human PBL did not proliferate or develop significant cytotoxicity when treated with rIL-2 because of the lack of p75 IL-2R expression. However, culture of isolated CD4+ T cells with immobilized anti-CD3 mAb plus rIL-2 resulted in a marked proliferation (500-fold increase in 14 days) of CD4+ T cells. The proliferating CD4+ T cells produced IL-2 (92 U/ml) and showed strong cytotoxicity against OKT3 hybridoma cells and Daudi, K562, and U937 tumor cells in an anti-CD3 mAb-dependent manner. The CD4+ T cells contained significant amounts of cytolytic granule-related proteins such as serine esterase and perforin. Activated CD4+ helper/killer cells can be generated from both healthy donors and tumor patients and can be propagated in vitro for 14 to 35 days by biweekly restimulation with immobilized anti-CD3 mAb plus rIL-2. This culture yielded about 20,000-fold increase in cell number after a 21-day culture. Bispecific antibody containing anti-CD3 and anti-glioma Fab components enhanced the cytotoxicity of activated CD4+ helper/killer cells against IMR32 glioma cells. Moreover, the activated CD4+ helper/killer cells showed both helper and antitumor activity in vivo and prevented growth of anti-CD3 hybridoma cells in nude mice whether or not IL-2 was administered. These results indicate that anti-CD3 mAb plus IL-2-activated CD4+ helper/killer cells may provide an effective strategy for adoptive tumor immunotherapy of cancer.